Analysis of 2012-2021 commercial claims demonstrates that spending growth was concentrated among the highest spenders and there was increasing subsidy across enrollees through cost-sharing design.
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results